SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more

 We are pausing publication of The Daily Briefing out of respect for the tragic passing of Brian Thompson. We will resume publication of this daily newsletter in the coming days.

Expert Insight

How the cell and gene therapy pipeline will change the status quo

The pipeline of cell and gene therapies is expanding in both depth and breadth. Healthcare leaders must adapt as competition grows and innovation stretches into new specialties. Find out how new cell and gene therapies will change the status quo and what it means for providers, purchasers, and pharmaceutical manufacturers.

The future includes drugs for a wide variety of conditions

The pipeline for cell and gene therapies (CGT) is booming. Over 650 products are in phase II and beyond.1 While most CGT products today are for oncological and hematological conditions, many pipeline therapies are expanding into other areas. Cell and gene therapies are in development for use in specialties like neurology and cardiology, where providers have limited experience with such treatments. For example, cell therapies for amyotrophic lateral sclerosis (ALS) and gene therapies for coronary artery disease (CAD) are in phase III clinical trials.1


SPONSORED BY

INTENDED AUDIENCE
  • Health plans
  • Hospitals and health systems
  • Pharmacy, diagnostics, and lab

AFTER YOU READ THIS
  • You will understand how the cell and gene therapy pipeline is growing both in volume and across disease states.
  • You will learn how healthcare stakeholders can respond to and prepare for the cell and gene therapy pipeline.

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.